Clinical characteristics of patients with marker chromosomes
. | No marker (n = 861) . | Marker (n = 165) . | P value* . |
---|---|---|---|
Age, y (median, range) | 55 (17-83) | 58 (15-77) | .002 |
Sex, % (male/female) | 53.0/47.0 | 53.9/46.1 | .93 |
FAB code | .006 | ||
FAB M0 (%) | 67/807 (8.3) | 11/147 (7.5) | |
FAB M1 (%) | 166/ 807 (20.6) | 23/147 (15.6) | |
FAB M2 (%) | 238/807 (29.5) | 57/147 (38.8) | |
FAB M4/M5 (%) | 275/807 (34.1) | 32/147 (21.8) | |
FAB M6 (%) | 32/807 (4.0) | 14/147 (9.5) | |
FAB M7 (%) | 11/ 807 (1.4) | 1/147 (0.7) | |
RAEB (%) | 18/807 (2.2) | 9/147 (6.1) | |
Prior MDS (%) | 166/849 (19.6) | 38/163 (23.3) | .93 |
Therapy-related AML (%) | 63/849 (7.4) | 18/163 (11.0) | .82 |
BM blasts, % (median, range) | 61 (6-99) | 48 (5-95) | <.001 |
Leukocytes, /nL (median, range) | 10.39 (0.2-465.9) | 3.95 (0.6-171.3) | <.001 |
Platelets, /nL (median, range) | 55 (1-1043) | 40.5 (4-433) | .002 |
LDH value, U/L (median, range) | 415 (27-7369) | 324 (97-5489) | .24 |
. | No marker (n = 861) . | Marker (n = 165) . | P value* . |
---|---|---|---|
Age, y (median, range) | 55 (17-83) | 58 (15-77) | .002 |
Sex, % (male/female) | 53.0/47.0 | 53.9/46.1 | .93 |
FAB code | .006 | ||
FAB M0 (%) | 67/807 (8.3) | 11/147 (7.5) | |
FAB M1 (%) | 166/ 807 (20.6) | 23/147 (15.6) | |
FAB M2 (%) | 238/807 (29.5) | 57/147 (38.8) | |
FAB M4/M5 (%) | 275/807 (34.1) | 32/147 (21.8) | |
FAB M6 (%) | 32/807 (4.0) | 14/147 (9.5) | |
FAB M7 (%) | 11/ 807 (1.4) | 1/147 (0.7) | |
RAEB (%) | 18/807 (2.2) | 9/147 (6.1) | |
Prior MDS (%) | 166/849 (19.6) | 38/163 (23.3) | .93 |
Therapy-related AML (%) | 63/849 (7.4) | 18/163 (11.0) | .82 |
BM blasts, % (median, range) | 61 (6-99) | 48 (5-95) | <.001 |
Leukocytes, /nL (median, range) | 10.39 (0.2-465.9) | 3.95 (0.6-171.3) | <.001 |
Platelets, /nL (median, range) | 55 (1-1043) | 40.5 (4-433) | .002 |
LDH value, U/L (median, range) | 415 (27-7369) | 324 (97-5489) | .24 |
BM blasts, bone marrow blast percentage; FAB, French-American-British; LDH, lactate dehydrogenase.
Adjusted for multiple testing.